Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer

Epigenetics

Volumn 9, Issue 6, 2014, Pages 918-927

  Sharad, Shashwat ^a   Ravindranath, Lakshmi ^a   Haffner, Michael C ^b   Li, Hua ^a   Yan, Wusheng ^a   Sesterhenn, Isabell A ^c   Chen, Yongmei ^a   Ali, Amina ^a,d   Srinivasan, Alagarsamy ^a   McLeod, David G ^a,d   Yegnasubramanian, Srinivasan ^b   Srivastava, Shiv ^a   Dobi, Albert ^a   Petrovics, Gyorgy ^a  

^a Uniformed Services University of the Health Sciences   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOINT PATHOLOGY CENTER   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Androgen receptor; Laser capture microdissection; Methylation; PMEPA1; Prostate cancer; Tumor suppressor

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANDROGEN RECEPTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; RESTRICTION ENDONUCLEASE; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE NEDD4; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; DECITABINE; MEMBRANE PROTEIN; PMEPA1 PROTEIN, HUMAN;

AFRICAN AMERICAN; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; EUROPEAN AMERICAN; GENE; GENE EXPRESSION; GENE SILENCING; GSTP1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; LINE1 GENE; MAJOR CLINICAL STUDY; MALE; METHYLATION; PMEPA1 GENE; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING; AGED; ANALOGS AND DERIVATIVES; CAUCASIAN; CPG ISLAND; DNA METHYLATION; GENETICS; INTRON; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

AFRICAN AMERICANS; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BASE SEQUENCE; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE EXPRESSION; HUMANS; INTRONS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, MESSENGER;

EID: 84901805279     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.28710     Document Type: Article

References (45)

1. Berman DM, Rodriguez R, Veltri RW. Development, Molecular Biology, and Physiology of the Prostate. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Campbell-Walsh Urology 10th Edition Review. Philadelphia: Saunders, Elsevier Inc., 2012: 2533-2569. e11.
2. Schmidt LJ, Tindall DJ. Androgen receptor: past, present and future. Curr Drug Targets 2013; 14:401-7; PMID:23565753; http://dx.doi. org/10.2174/1389450111314040002
3. Dobi A, Sreenath T, Srivastava S. Androgen-Dependent Oncogenic Activation of ETS Transcription Factors by Recurrent Gene Fusions in Prostate Cancer: Biological and Clinical Implications. In: Wang Z. Androgen-Responsive Genes in Prostate Cancer-Regulation, Function and Clinical Applications. New York: Springer Science; 2013:307-28.
4. Wen S, Niu Y, Lee SO, Chang C. Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death. Cancer Treat Rev 2014;40:31-40; http://dx.doi.org/10.1016/j. ctrv.2013.07.008; PMID:23993415
5. Madan RA, Shah AA, Dahut WL. Is it time to reevaluate definitive therapy in prostate cancer? J Natl Cancer Inst 2013; 105:683-5; PMID:23615688; http://dx.doi.org/10.1093/jnci/djt094
6. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324:787-90; PMID:19359544; http://dx.doi. org/10.1126/science.1168175
7. Mohler JL, Titus MA, Wilson EM. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res 2011; 17:5844-9; PMID:21705451; http://dx.doi. org/10.1158/1078-0432.CCR-11-0644
8. Chang KH, Li R, Kuri B, Lotan Y, Roehrborn CG, Liu J, Vessella R, Nelson P, Kapur P, Guo X, et al. A gain-of-function mutation in DHT synthesis in CRPC. Cell 2013; 154:1074-84; PMID:23993097; http://dx.doi.org/10.1016/j.cell.2013.07.029
9. Eichholz A, Ferraldeschi R, Attard G, de Bono JS. Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer. Mol Cell Endocrinol 2012; 360:68-75; PMID:21986558; http://dx.doi.org/10.1016/j.mce.2011.09.038
10. Dobi A, Furusato B, Shaheduzzaman S, Chen Y, Vahey M, Nydam T, Sesterhenn IA, McLeod DG, Petrovics G, Srivastava S. ERG expression levels in prostate tumors reflect functional status of the androgen receptor (AR) as a consequence of fusion of ERG with AR regulated gene promoters. The Open Cancer J 2010; 3:101-8
11. Gsponer JR, Braun M, Scheble VJ, Zellweger T, Bachmann A, Perner S, Vlajnic T, Srivastava M, Tan SH, Dobi A, et al. ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2014; (Forthcoming); PMID:24469092; http://dx.doi. org/10.1038/pcan.2013.62
12. Xu LL, Su YP, Labiche R, Segawa T, Shanmugam N, McLeod DG, Moul JW, Srivastava S. Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. Int J Cancer 2001; 92:322-8; PMID:11291065; http://dx.doi.org/10.1002/ijc.1196
13. Xu LL, Shanmugam N, Segawa T, Sesterhenn IA, McLeod DG, Moul JW, Srivastava S. A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate. Genomics 2000; 66:257-63; PMID:10873380; http://dx.doi.org/10.1006/geno.2000.6214
14. Masuda K, Werner T, Maheshwari S, Frisch M, Oh S, Petrovics G, May K, Srikantan V, Srivastava S, Dobi A. Androgen receptor binding sites identified by a GREF_GATA model. J Mol Biol 2005; 353:763-71; PMID:16213525; http://dx.doi.org/10.1016/j. jmb.2005.09.009
15. Xu LL, Shi Y, Petrovics G, Sun C, Makarem M, Zhang W, Sesterhenn IA, McLeod DG, Sun L, Moul JW, et al. PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression. Cancer Res 2003; 63:4299-304; PMID:12907594
16. Li H, Xu LL, Masuda K, Raymundo E, McLeod DG, Dobi A, Srivastava S. A feedback loop between the androgen receptor and a NEDD4-binding protein, PMEPA1, in prostate cancer cells. J Biol Chem 2008; 283:28988-95; PMID:18703514; http://dx.doi. org/10.1074/jbc.M710528200
17. Brunschwig EB, Wilson K, Mack D, Dawson D, Lawrence E, Willson JK, Lu S, Nosrati A, Rerko RM, Swinler S, et al. PMEPA1, a transforming growth factor-beta-induced marker of terminal colonocyte differentiation whose expression is maintained in primary and metastatic colon cancer. Cancer Res 2003; 63:1568-75; PMID:12670906
18. Watanabe Y, Itoh S, Goto T, Ohnishi E, Inamitsu M, Itoh F, Satoh K, Wiercinska E, Yang W, Shi L, et al. TMEPAI, a transmembrane TGF-betainducible protein, sequesters Smad proteins from active participation in TGF-beta signaling. Mol Cell 2010; 37:123-34; PMID:20129061; http://dx.doi. org/10.1016/j.molcel.2009.10.028
19. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19:575-86; PMID:21575859; http://dx.doi. org/10.1016/j.ccr.2011.04.008
20. Liu R, Zhou Z, Huang J, Chen C. PMEPA1 promotes androgen receptor-negative prostate cell proliferation through suppressing the Smad3/4-c-Myc-p21 Cip1 signaling pathway. J Pathol 2011; 223:683-94; PMID:21341270; http://dx.doi.org/10.1002/ path.2834
21. Richter E, Masuda K, Cook C, Ehrich M, Tadese AY, Li H, Owusu A, Srivastava S, Dobi A. A role for DNA methylation in regulating the growth suppressor PMEPA1 gene in prostate cancer. Epigenetics 2007; 2:100-9; PMID:18174752; http://dx.doi. org/10.4161/epi.2.2.4611
22. Lin X, Tascilar M, Lee WH, Vles WJ, Lee BH, Veeraswamy R, Asgari K, Freije D, van Rees B, Gage WR, et al. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol 2001; 159:1815-26; PMID:11696442; http://dx.doi. org/10.1016/S0002-9440(10)63028-3
23. Yegnasubramanian S, Lin X, Haffner MC, DeMarzo AM, Nelson WG. Combination of methylated-DNA precipitation and methylation-sensitive restriction enzymes (COMPARE-MS) for the rapid, sensitive and quantitative detection of DNA methylation. Nucleic Acids Res 2006; 34:e19; PMID:16473842; http://dx.doi.org/10.1093/nar/gnj022
24. Yang AS, Estécio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004; 32:e38; PMID:14973332; http://dx.doi.org/10.1093/nar/ gnh032
25. Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem 2004; 91:540-52; PMID:14755684; http://dx.doi.org/10.1002/ jcb.10740
26. Rosen P, Pfister D, Young D, Petrovics G, Chen Y, Cullen J, Böhm D, Perner S, Dobi A, McLeod DG, et al. Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology 2012; 80:749-53; PMID:22950997; http:// dx.doi.org/10.1016/j.urology.2012.07.001
27. Farrell J, Petrovics G, McLeod DG, Srivastava S. Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. Int J Mol Sci 2013; 14:15510-31; PMID:23892597; http://dx.doi.org/10.3390/ ijms140815510
28. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212-36; PMID:21685461; http://dx.doi.org/10.3322/caac.20121
29. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004; 64:1975-86; PMID:15026333; http://dx.doi. org/10.1158/0008-5472.CAN-03-3972
30. Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, Esopi D, Irizarry RA, Getzenberg RH, Nelson WG, et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med 2013; 5:169ra10; PMID:23345608; http://dx.doi.org/10.1126/scitranslmed.3005211
31. Shaheduzzaman S, Vishwanath A, Furusato B, Cullen J, Chen Y, Bañez L, Nau M, Ravindranath L, Kim KH, Mohammed A, et al. Silencing of Lactotransferrin expression by methylation in prostate cancer progression. Cancer Biol Ther 2007; 6:1088-95; PMID:17568188; http://dx.doi.org/10.4161/ cbt.6.7.4327
32. Nelson WG, De Marzo AM, Yegnasubramanian S. Epigenetic alterations in human prostate cancers. Endocrinology 2009; 150:3991-4002; PMID:19520778; http://dx.doi.org/10.1210/ en.2009-0573
33. Martin DN, Starks AM, Ambs S. Biological determinants of health disparities in prostate cancer. Curr Opin Oncol 2013; 25:235-41; PMID:23399519
34. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Pookot D, Li LC, Tabatabai ZL, Kawahara M, Nakagawa M, et al. Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer. Int J Cancer 2005; 116:174-81; PMID:15800905; http://dx.doi. org/10.1002/ijc.21017
35. Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R, Klein E, Rubin MA, Zhou M. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 2011; 71:489-97; PMID:20878952; http:// dx.doi.org/10.1002/pros.21265
36. Mao X, Yu Y, Boyd LK, Ren G, Lin D, Chaplin T, Kudahetti SC, Stankiewicz E, Xue L, Beltran L, et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res 2010; 70:5207-12; PMID:20516122; http://dx.doi. org/10.1158/0008-5472.CAN-09-4074
37. Blattner M, Lee DJ, O'Reilly C, Park K, Macdonald TY, Khani F, Turner KR, Chiu YL, Wild PJ, Dolgalev I, et al. SPOP Mutations in Prostate Cancer across Demographically Diverse Patient Cohorts. Neoplasia 2014; 16:14-20; PMID:24563616
38. Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, Luna R, Rashid A, Shen L, Estecio MR, et al. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res 2006; 66:5495-503; PMID:16707479; http://dx.doi.org/10.1158/0008-5472.CAN-05-2385
39. Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu Rev Pharmacol Toxicol 2009; 49:243-63; PMID:18851683; http://dx.doi. org/10.1146/annurev-pharmtox-061008-103102
40. Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, Chen Y, Nau M, Ravindranath L, Chen Y, Dobi A, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005; 24:3847-52; PMID:15750627; http://dx.doi.org/10.1038/sj.onc.1208518
41. Hu Y, Dobi A, Sreenath T, Cook C, Tadase AY, Ravindranath L, Cullen J, Furusato B, Chen Y, Thangapazham RL, et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res 2008; 14:4719-25; PMID:18676740; http:// dx.doi.org/10.1158/1078-0432.CCR-08-0531
42. Sterbis JR, Gao C, Furusato B, Chen Y, Shaheduzzaman S, Ravindranath L, Osborn DJ, Rosner IL, Dobi A, McLeod DG, et al. Higher expression of the androgen-regulated gene PSA/ HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival. Clin Cancer Res 2008; 14:758-63; PMID:18245536; http://dx.doi. org/10.1158/1078-0432.CCR-07-1356
43. Derosa CA, Furusato B, Shaheduzzaman S, Srikantan V, Wang Z, Chen Y, Seifert M, Ravindranath L, Young D, Nau M, et al. Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression. Prostate Cancer Prostatic Dis 2012; 15:150-6; PMID:22343836; http://dx.doi. org/10.1038/pcan.2011.61
44. Sun M, Srikantan V, Ma L, Li J, Zhang W, Petrovics G, Makarem M, Strovel JW, Horrigan SG, Augustus M, et al. Characterization of frequently deleted 6q locus in prostate cancer. DNA Cell Biol 2006; 25:597-607; PMID:17132090; http://dx.doi. org/10.1089/dna.2006.25.597
45. Mohamed AA, Tan SH, Sun C, Shaheduzzaman S, Hu Y, Petrovics G, Chen Y, Sesterhenn IA, Li H, Sreenath T, et al. ERG oncogene modulates prostaglandin signaling in prostate cancer cells. Cancer Biol Ther 2011; 11:410-7; PMID:21178489; http:// dx.doi.org/10.4161/cbt.11.4.14180